Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH138889D
  • |
  • Pages: 109
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company's pharmaceutical products include metabolism and digestive system, cardiovascular system, blood system, central nervous system drugs, anti-infection, anti-tumor, vaccine and raw material and intermediates. It provides medical diagnostic products such as real time PCR detector, human papillomavirus assay kit, HBV quantitative reagent, and biofosun microorganism identification and susceptibility analysis system. The company's research and development unit concentrates on therapeutic areas of metabolism and digestive system, blood system, cardiovascular system and central nervous system. Fosun Pharma is headquartered in Shanghai City, Shanghai, China.

Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

Novartis May Sell US Generic Pill Business 19

Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 21

Venture Financing 22

Ambrx Raises USD45 Million in Venture Financing 22

Saladax Biomedical Raises USD 23 Million In Series D Venture Financing 24

Private Equity 26

KKR Receives Government Approval To Acquire 35% Stake In Gland Pharma For USD200 Million 26

Partnerships 27

AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 27

Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 28

Marubeni to Form Joint Venture with Shanghai Fosun Pharma 29

Kite Pharma Forms Joint Venture with Fosun Pharma 30

Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 31

Dr. Reddy's Labs Enters into Co-Marketing Agreement with Gland Pharma 32

Nature's Sunshine Products Forms Joint Venture with Fosun Pharma 33

Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 34

Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 35

Atrium Innovations Forms Joint Venture With Fosun Industrial 36

Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 37

Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 38

Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 39

Licensing Agreements 40

Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial-Portela 40

Athenex to Enter into Licensing Agreement with Gland Pharma 41

Athenex to Enter into Licensing Agreement with Gland Pharma 42

Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 43

Sirona Biochem Enters into Licensing Agreement with Wanbang Biopharma for SGLT2 Inhibitor 44

TB Alliance Enters Into Licensing Agreement With Fosun Pharma 46

Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 47

Equity Offering 48

Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 48

Gland Pharma May Raise USD500 Million in IPO 50

Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 51

Chindex to Raise USD38.2 Million in Private Placement of Shares 53

Phagelux Raises Funds through Private Placement 54

Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 55

Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 56

Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 57

Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 58

Nature's Sunshine Raises USD46 Million in Private Placement of Shares 59

Shanghai Fosun Pharma Prices Private Placement Of Shares For USD 229.6 Million 61

Debt Offering 62

Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 62

Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 63

Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 64

Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 65

Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 66

Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 67

Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 68

Asset Transactions 69

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 69

Acquisition 70

Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 70

Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 71

Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 73

Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 74

Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 76

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 77

Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To USD 304 Million 78

Winteam Pharma Completes Acquisition Of Tongjitang Chinese Medicines From Hanmax And Fosun International For USD 426.4 Million 79

Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81

Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82

Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For USD 93 Million 83

Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84

Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85

Fosun Pharma Acquires 11% Stake In Shenzhen Belter For USD 7 Million 86

Shanghai Fosun Pharmaceutical (Group) Co Ltd-Key Competitors 87

Shanghai Fosun Pharmaceutical (Group) Co Ltd-Key Employees 88

Shanghai Fosun Pharmaceutical (Group) Co Ltd-Locations And Subsidiaries 90

Head Office 90

Other Locations & Subsidiaries 90

Recent Developments 91

Strategy And Business Planning 91

Nov 15, 2017: Fosun Pharma set up Suzhou R & D Center 91

Jul 11, 2017: Rooted in Shanghai innovation Fosun Pharma Zhangjiang new R & D headquarters base was officially launched 92

Financial Announcements 94

Mar 27, 2018: Fosun pharma: Announcement of Final Results for the Year Ended 31 December 2017 94

Oct 31, 2017: Fosun Pharma releases third quarter 2017 revenue up 21.83% YoY Research and development investment continues to increase 96

Aug 30, 2017: Fosun Pharma: R & D and international lighting performance, the first half revenue grew 20.41% 97

Jun 14, 2017: Fosun Pharma released first quarter 2017 revenue up 20.29% R & D investment continued to increase 99

Mar 31, 2017: Fosun Pharma non-net profit in 2016 increased by 26.36% year-on-year Continued to increase innovation and R & D investment Strengthen the layout of medical services 100

Corporate Communications 103

Mar 26, 2018: Change In Fosun Pharma's Board Of Directors To Further Align Group Strategy 103

Mar 26, 2018: Shanghai Fosun Pharmaceutical Announces Personnel Changes 104

Sep 05, 2017: Fosun Pharmas Subsidiary Sisram, the World's Leading Energy-Based Medical Aesthetic Treatment Systems Provider, to be Listed as the First Israeli Company on the Main Board of SEHK 106

Product Approvals 108

Oct 29, 2017: Fosun Pharma treatment of leukemia new drug approved by the FDA drug clinical trials 108

Appendix 109

Methodology 109

About GlobalData 109

Contact Us 109

Disclaimer 109

List of Figures

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

List of Tables

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Novartis May Sell US Generic Pill Business 19

Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 21

Ambrx Raises USD45 Million in Venture Financing 22

Saladax Biomedical Raises USD 23 Million In Series D Venture Financing 24

KKR Receives Government Approval To Acquire 35% Stake In Gland Pharma For USD200 Million 26

AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 27

Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 28

Marubeni to Form Joint Venture with Shanghai Fosun Pharma 29

Kite Pharma Forms Joint Venture with Fosun Pharma 30

Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 31

Dr. Reddy's Labs Enters into Co-Marketing Agreement with Gland Pharma 32

Nature's Sunshine Products Forms Joint Venture with Fosun Pharma 33

Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 34

Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 35

Atrium Innovations Forms Joint Venture With Fosun Industrial 36

Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 37

Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 38

Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 39

Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial-Portela 40

Athenex to Enter into Licensing Agreement with Gland Pharma 41

Athenex to Enter into Licensing Agreement with Gland Pharma 42

Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 43

Sirona Biochem Enters into Licensing Agreement with Wanbang Biopharma for SGLT2 Inhibitor 44

TB Alliance Enters Into Licensing Agreement With Fosun Pharma 46

Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 47

Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 48

Gland Pharma May Raise USD500 Million in IPO 50

Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 51

Chindex to Raise USD38.2 Million in Private Placement of Shares 53

Phagelux Raises Funds through Private Placement 54

Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 55

Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 56

Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 57

Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 58

Nature's Sunshine Raises USD46 Million in Private Placement of Shares 59

Shanghai Fosun Pharma Prices Private Placement Of Shares For USD 229.6 Million 61

Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 62

Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 63

Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 64

Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 65

Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 66

Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 67

Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 68

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 69

Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 70

Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 71

Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 73

Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 74

Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 76

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 77

Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To USD 304 Million 78

Winteam Pharma Completes Acquisition Of Tongjitang Chinese Medicines From Hanmax And Fosun International For USD 426.4 Million 79

Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81

Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82

Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For USD 93 Million 83

Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84

Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85

Fosun Pharma Acquires 11% Stake In Shenzhen Belter For USD 7 Million 86

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Key Competitors 87

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Key Employees 88

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Subsidiaries 90

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Shanghai Fosun Pharmaceutical (Group) Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17840
Site License
USD 500 INR 35680
Corporate User License
USD 750 INR 53520

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com